These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 31236688)

  • 21. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.
    Halilbasic E; Fiorotto R; Fickert P; Marschall HU; Moustafa T; Spirli C; Fuchsbichler A; Gumhold J; Silbert D; Zatloukal K; Langner C; Maitra U; Denk H; Hofmann AF; Strazzabosco M; Trauner M
    Hepatology; 2009 Jun; 49(6):1972-81. PubMed ID: 19475687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.
    Fickert P; Pollheimer MJ; Silbert D; Moustafa T; Halilbasic E; Krones E; Durchschein F; Thüringer A; Zollner G; Denk H; Trauner M
    J Hepatol; 2013 Jun; 58(6):1201-8. PubMed ID: 23369794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toxicity of ethanol and acetaldehyde in hepatocytes treated with ursodeoxycholic or tauroursodeoxycholic acid.
    Henzel K; Thorborg C; Hofmann M; Zimmer G; Leuschner U
    Biochim Biophys Acta; 2004 Feb; 1644(1):37-45. PubMed ID: 14741743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perinatal exposure to UDCA prevents neonatal cholestasis in Cyp2c70
    de Vries HD; Palmiotti A; Li R; Hovingh MV; Mulder NL; Koehorst M; Bloks VW; van Zutphen T; Kuipers F; de Boer JF
    Pediatr Res; 2023 May; 93(6):1582-1590. PubMed ID: 36151295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases.
    Festi D; Montagnani M; Azzaroli F; Lodato F; Mazzella G; Roda A; Di Biase AR; Roda E; Simoni P; Colecchia A
    Curr Clin Pharmacol; 2007 May; 2(2):155-77. PubMed ID: 18690863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases.
    Trauner M; Graziadei IW
    Aliment Pharmacol Ther; 1999 Aug; 13(8):979-96. PubMed ID: 10468672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tauroursodeoxycholic acid protects cholestasis in rat reperfused livers: its roles in hepatic calcium mobilization.
    Ono T; Imai K; Kohno H; Uchida M; Takemoto Y; Dhar DK; Nagasue N
    Dig Dis Sci; 1998 Oct; 43(10):2201-10. PubMed ID: 9790455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatoprotection in ethinylestradiol-treated rats is provided by tauroursodeoxycholic acid, but not by ursodeoxycholic acid.
    Azer SA; Canfield PJ; Stacey NH
    J Gastroenterol Hepatol; 1995; 10(3):261-9. PubMed ID: 7548801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale for therapy with ursodeoxycholic acid in patients with cholestatic liver disease.
    van Erpecum KJ; van de Meeberg PC; van Berge Henegouwen GP
    Neth J Med; 1993 Dec; 43(5-6):233-8. PubMed ID: 8107930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis.
    Beraza N; Ofner-Ziegenfuss L; Ehedego H; Boekschoten M; Bischoff SC; Mueller M; Trauner M; Trautwein C
    Gut; 2011 Mar; 60(3):387-96. PubMed ID: 21115542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel Aspects in the Management of Cholestatic Liver Diseases.
    Chazouillères O
    Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
    Munoz-Garrido P; Marin JJ; Perugorria MJ; Urribarri AD; Erice O; Sáez E; Úriz M; Sarvide S; Portu A; Concepcion AR; Romero MR; Monte MJ; Santos-Laso Á; Hijona E; Jimenez-Agüero R; Marzioni M; Beuers U; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Drenth JP; Banales JM
    J Hepatol; 2015 Oct; 63(4):952-61. PubMed ID: 26044126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.
    Trauner M; Halilbasic E; Claudel T; Steinacher D; Fuchs C; Moustafa T; Pollheimer M; Krones E; Kienbacher C; Traussnigg S; Kazemi-Shirazi L; Munda P; Hofer H; Fickert P; Paumgartner G
    Dig Dis; 2015; 33(3):433-9. PubMed ID: 26045280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential regulation of cyclin D1 and cell death by bile acids in primary rat hepatocytes.
    Castro RE; Amaral JD; Solá S; Kren BT; Steer CJ; Rodrigues CM
    Am J Physiol Gastrointest Liver Physiol; 2007 Jul; 293(1):G327-34. PubMed ID: 17431217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review: The bile acids urso- and tauroursodeoxycholic acid as neuroprotective therapies in retinal disease.
    Daruich A; Picard E; Boatright JH; Behar-Cohen F
    Mol Vis; 2019; 25():610-624. PubMed ID: 31700226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of rat hepatocyte proliferation by bile salts: in vitro and in vivo studies.
    Barone M; Francavilla A; Polimeno L; Ierardi E; Romanelli D; Berloco P; Di Leo A; Panella C
    Hepatology; 1996 May; 23(5):1159-66. PubMed ID: 8621149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apoptosis and modulation of cell cycle control by bile acids in human leukemia T cells.
    Fimognari C; Lenzi M; Cantelli-Forti G; Hrelia P
    Ann N Y Acad Sci; 2009 Aug; 1171():264-9. PubMed ID: 19723064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 24-Norursodeoxycholic acid reshapes immunometabolism in CD8
    Zhu C; Boucheron N; Müller AC; Májek P; Claudel T; Halilbasic E; Baazim H; Lercher A; Viczenczova C; Hainberger D; Preglej T; Sandner L; Alteneder M; Gülich AF; Khan M; Hamminger P; Remetic J; Ohradanova-Repic A; Schatzlmaier P; Donner C; Fuchs CD; Stojakovic T; Scharnagl H; Sakaguchi S; Weichhart T; Bergthaler A; Stockinger H; Ellmeier W; Trauner M
    J Hepatol; 2021 Nov; 75(5):1164-1176. PubMed ID: 34242699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis.
    Macias RI; Serrano MA; Monte MJ; Jimenez S; Hernandez B; Marin JJ
    J Pharmacol Exp Ther; 2005 Feb; 312(2):751-8. PubMed ID: 15452192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease.
    Steinacher D; Claudel T; Trauner M
    Dig Dis; 2017; 35(3):282-287. PubMed ID: 28249257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.